HCW appoints Arce as equity research MD

H.C. Wainwright & Co. LLC has hired Ed Arce as managing director in equity research. Previously, Arce worked at Roth Capital Partners where he served as a senior research analyst of biopharmaceuticals and specialty pharmaceuticals.


NEW YORK–(BUSINESS WIRE)–H.C. Wainwright & Co., LLC (“HCW”) announced today that Ed Arce has joined the firm as a Managing Director in Equity Research. Mr. Arce will be a Senior Analyst covering companies in the Biopharmaceuticals and Specialty Pharmaceuticals sectors.

Mr. Arce joins HCW from Roth Capital Partners, where he was a Senior Research Analyst – Biopharmaceuticals and Specialty Pharmaceuticals. Prior to that, he was a member of the biotechnology research teams at MLV & Co., Wedbush PacGrow Life Sciences, UBS and First Albany.

“We are excited that Ed has decided to join the Biotechnology Research team at HCW as we continue to expand our footprint and capacity in this sector,” commented Mark Viklund, Chief Executive Officer of HCW. “Ed’s expertise in Biopharma and Specialty Pharma will complement and enhance our capabilities within this sector of life sciences.”

About H.C. Wainwright & Co., LLC
H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H.C. Wainwright team has been the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. H. C. Wainwright was established in 1868 and is headquartered in New York City.